Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Revenio: iCare and Evolucare have launched a distribution partnership in AI solutions

By Juha KinnunenAnalyst
Revenio Group

Translation: Original comment published in Finnish on 5/8/2023 at 10:55 am.

iCare and OphtAI, a French Evolucare Technologies company, have launched a distribution partnership. iCare will now offer OphtAI analysis in EMEA and Canada for its iCare ILLUME retinal screening solution based on retinal images. The news does not affect our estimates or our view of Revenio, but we see this as a positive step on the company's path towards more holistic solutions.

OphtAI included in the range of services

Revenio has previously worked with Thirona, an AI service, but it has been known that more AI partners are on the way. The ILLUME platform is independent of the AI provider, so Revenio can establish new AI partnerships and easily add them to the platform. OphtAI expands Revenio's offering and is particularly strong in France, but the partnership covers the whole of EMEA and Canada. iCare has been a distributor of Thirona's AI service in Europe, but to our understanding, not in Canada.

In the future, Revenio's product and service range will certainly be expanded to other regions, the most interesting of which is the United States. However, the path there is longer because FDA approval must be obtained for the combination of device and AI solution, meaning that separate approvals for the device and AI are not enough. Yet another AI partner could be utilized as well.

OphtAI is one of the major AI providers in the sector

OphtAI is one of the most advanced AI retinal image analysis providers. The iCare ILLUME retinal screening solution uses AI-generated image analysis for diabetic retinopathy screening and, in the future, for other eye diseases. Revenio has validated the performance of the OphtAI solution.

At the heart of the iCare ILLUME solution that supports clinical decision-making is the high-quality image data generated by iCare's fundus imaging devices and the associated cloud-based software solution. Artificial intelligence enables the efficient processing of large numbers of images, thereby improving screening accessibility. The holistic solution optimizes patient care pathways and the processes of eye care professionals.

Login required

This content is only available for logged in users

Create account

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more on company page

Key Estimate Figures28.04.2023

202223e24e
Revenue97.0110.8129.1
growth-%23.1 %14.3 %16.5 %
EBIT (adj.)30.933.439.1
EBIT-% (adj.)31.8 %30.1 %30.3 %
EPS (adj.)0.860.951.14
Dividend0.360.410.55
Dividend %0.9 %1.8 %2.4 %
P/E (adj.)44.624.020.0
EV/EBITDA30.616.113.4

Forum discussions

The FDA has announced this week that it is changing its practices regarding medical device approval applications. Device manufacturers can now...
7 hours ago
by MolskisPabrai
12
Q3 was indeed rather boring, and it seems Q4 is progressing along the same lines. Reve also keeps a lower profile than before; they didn’t even...
12/5/2025, 2:12 PM
by Von Wangell
13
Revenio’s trading volume today, with a rising share price, is many times higher than normal. Those in the know, know, I don’t…
11/25/2025, 7:50 PM
by Sissos
16
The costs of disposable instruments were investigated in a US study, including those for rebound tonometry probes. The data is based on a clinic...
11/10/2025, 11:07 AM
by veronmaksaja
5
op-media.fi – 14 Oct 25 Osakkeiden top 10 – Nämä ovat ammattilaisten valinnat pitkän aikavälin... Asiantuntijat listasivat kotimaiset yhtiöt...
11/9/2025, 3:13 PM
by Sissos
12
In past quarters, there have been one-off costs which, reading between the lines, have been related to potential acquisitions. One would gradually...
11/9/2025, 7:59 AM
by Temew
12
More precious than gold? Revenio’s stock is highly valued. DCF shows 28€ if operating profit doubles in 5 years.
10/31/2025, 10:33 AM
by LeFevre
16
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.